Form 4: Pyxis Oncology SVP, Chief Accounting Officer Jitendra Wadhane Reports Acquisition and Disposal of Common Stock

Jitendra Wadhane, SVP, Chief Accounting Officer of Pyxis Oncology, reports acquiring and disposing of common stock on March 26, 2024.

Summary

• On March 26, 2024, Jitendra Wadhane, SVP, Chief Accounting Officer of Pyxis Oncology, engaged in transactions involving the company's common stock.
• Wadhane acquired 131,484 shares of common stock at $0.
• Wadhane disposed of 398,421 shares of common stock.
• Following these transactions, Wadhane beneficially owns 398,421 shares of Pyxis Oncology common stock.
• The acquired shares represent restricted stock units vesting over time, contingent upon continued employment.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company officer. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Future Outlook

The restricted stock units vest over time, contingent upon continued employment, suggesting a long-term incentive for the reporting person.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor the actions of key personnel.

Stakeholder Impact

• Shareholders can use this information to understand the actions of company insiders and their alignment with shareholder interests.

Key Dates